Latest Breaking News On - Global external affairs - Page 8 : comparemela.com

INVENTIVA: Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China

Chia Tai Tianqing Pharmaceutical Group Co., Ltd., a Sino Biopharm's subsidiary, receives IND approval from the NMPA to initiate the clinical development in mainland China of lanifibranor in NASHSino Biopharm

United statesNew yorkUnited kingdomPascaline clercGewinn nurSino biopharmAude lepreuxPhilip duongDtx pharmaPatricial bankHead of overseas bd allianceBrunswick groupChinese national medical products administrationChia tai tianqing pharmaceutical group co ltdGlobal external affairsExchange commission on

Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 25 May 2023

Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 25 May 2023
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

United statesAude lepreuxPascaline clercBrunswick groupGlobal external affairsExchange commission onPatricial bankOrdinary general meetingFrench labor codeEuronext parisNasdaq global marketGlobal externalPrivate securities litigation reform actNew drug applicationUniversal registration documentDes march

Stock Market | FinancialContent Business Page

FinancialContent fully hosted finance channel

United kingdomNew yorkUnited statesPascaline clercAude lepreuxPhilip duongSino biopharmPatricial bankBrunswick groupExchange commission onDtx pharmaHead of overseas bd allianceChia tai tianqing pharmaceutical group co ltdGlobal external affairsChinese national medical products administrationLong island city

INVENTIVA: Inventiva reports 2023 First Quarter Financial Information¹ and provides a corporate update

Cash and cash equivalents at €56.3 million, short-term deposits at €0.7 million2, and long term deposit at €9.3 million3 as of March 31, 2023, compared to €86.7 million, €1.0 million and €0.7 million as

Bruxelles capitaleNew yorkUnited statesSan diegoQuentin ansteeMichael cooremanAude lepreuxPascaline clercGewinn nurData monitoring committeeGlobal external affairsCompany natiBrunswick groupPatricial bankInternational liver congressExchange commission on

Inventiva reports 2023 First Quarter Financial Information¹ and provides a corporate update

Cash and cash equivalents at €56.3 million, short-term deposits at €0.7 million2, and long term deposit at €9.3 million3 as of March 31, 2023, compared to €86.7 million, €1.0. | May 16, 2023

United statesBruxelles capitaleSan diegoNew yorkAude lepreuxPascaline clercMichael cooremanQuentin ansteeInternational liver congressLife sciences metabolics dayBrunswick groupExchange commission onCompany natiPatricial bankAmerican diabetes associationData monitoring committee